Two of Israel’s leading financial news outlets, Globes and The Marker, reported on Sunday that Blavatnik has been examining a large share purchase in Teva, whose stock price hit a 17-year low last week after the company again cut its annual profit forecast.

The Marker reported that Blavatnik was looking to acquire up to a $3 billion stake in Teva. The company has a $12.3 billion market cap.

The investment could either be done through a private stock listing, which would help Teva deal with its nearly $35 billion debt burden, or the shares could be bought from pharmaceutical firm Allergan, the report said.

Allergan received a 10 percent stake in Teva as part of a 2016 deal in which Teva bought its generics business for $40.5 billion. Allergan announced last week that it would begin selling down that stake.

Blavatnik’s Access has investments in real estate, chemicals, media and technology with Warner Music among its highest profile businesses. (Reporting by Ari Rabinovitch, Tova Cohen and Steven Scheer; Editing by Keith Weir)